CN1148183C - 具有抗肿瘤作用的吲哚基-3-乙醛酸衍生物 - Google Patents

具有抗肿瘤作用的吲哚基-3-乙醛酸衍生物 Download PDF

Info

Publication number
CN1148183C
CN1148183C CNB998059234A CN99805923A CN1148183C CN 1148183 C CN1148183 C CN 1148183C CN B998059234 A CNB998059234 A CN B998059234A CN 99805923 A CN99805923 A CN 99805923A CN 1148183 C CN1148183 C CN 1148183C
Authority
CN
China
Prior art keywords
alkyl
acid
group
substituted
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998059234A
Other languages
English (en)
Chinese (zh)
Other versions
CN1299280A (zh
Inventor
��B���ƶ���
B·尼科尔
I·采兰伊
J·史密德特
P·艾米格
D·莱彻特
E·昆瑟尔
K·布鲁恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asta Medica GmbH
Original Assignee
Asta Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma AG filed Critical Asta Pharma AG
Publication of CN1299280A publication Critical patent/CN1299280A/zh
Application granted granted Critical
Publication of CN1148183C publication Critical patent/CN1148183C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
CNB998059234A 1998-04-02 1999-03-22 具有抗肿瘤作用的吲哚基-3-乙醛酸衍生物 Expired - Fee Related CN1148183C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814838.0 1998-04-02
DE19814838A DE19814838C2 (de) 1998-04-02 1998-04-02 Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung

Publications (2)

Publication Number Publication Date
CN1299280A CN1299280A (zh) 2001-06-13
CN1148183C true CN1148183C (zh) 2004-05-05

Family

ID=7863398

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998059234A Expired - Fee Related CN1148183C (zh) 1998-04-02 1999-03-22 具有抗肿瘤作用的吲哚基-3-乙醛酸衍生物

Country Status (32)

Country Link
US (4) US6232327B1 (enExample)
EP (1) EP1071420B1 (enExample)
JP (2) JP5253696B2 (enExample)
KR (1) KR100583545B1 (enExample)
CN (1) CN1148183C (enExample)
AR (1) AR018175A1 (enExample)
AT (1) ATE304352T1 (enExample)
AU (1) AU768510B2 (enExample)
BG (1) BG64838B1 (enExample)
BR (1) BR9909902A (enExample)
CA (1) CA2326833C (enExample)
DE (2) DE19814838C2 (enExample)
DK (1) DK1071420T3 (enExample)
EE (1) EE04354B1 (enExample)
ES (1) ES2249884T3 (enExample)
GE (1) GEP20032967B (enExample)
HR (1) HRP20000643A2 (enExample)
HU (1) HUP0101530A3 (enExample)
ID (1) ID26504A (enExample)
IL (2) IL138737A0 (enExample)
IS (1) IS2307B (enExample)
NO (1) NO327721B1 (enExample)
NZ (1) NZ507084A (enExample)
PL (1) PL192779B1 (enExample)
RS (1) RS49866B (enExample)
RU (1) RU2262339C2 (enExample)
SK (1) SK286393B6 (enExample)
TR (1) TR200002853T2 (enExample)
TW (1) TWI230608B (enExample)
UA (1) UA70942C2 (enExample)
WO (1) WO1999051224A1 (enExample)
ZA (1) ZA200006150B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
AU777725B2 (en) * 1999-09-17 2004-10-28 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
US6849656B1 (en) * 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
CA2391952C (en) * 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
GB9928696D0 (en) 1999-12-03 2000-02-02 Swan Thomas & Co Ltd Optical devices and methods of manufacture thereof
IT1315267B1 (it) 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
DE19962300A1 (de) 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
IT1318641B1 (it) 2000-07-25 2003-08-27 Novuspharma Spa Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
JP2005504790A (ja) 2001-09-13 2005-02-17 シンタ ファーマスーティカルズ コーポレイション 癌を治療するための３−グリオキシリルアミドインドール
TWI323658B (en) 2001-12-06 2010-04-21 Nat Health Research Institutes Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
TWI324596B (en) 2002-08-26 2010-05-11 Nat Health Research Institutes Imidazolamino compounds
JP2006510672A (ja) * 2002-12-10 2006-03-30 ワイス プラスミノーゲン活性化因子の阻害因子−１（ｐａｉ−１）の阻害剤としての置換インドールオキソ−アセチルアミノ酢酸誘導体
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318611A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
EP1484329A1 (de) * 2003-06-06 2004-12-08 Zentaris GmbH Indolderivate mit Apoptose induzierender Wirkung
JP4878285B2 (ja) * 2003-06-05 2012-02-15 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング アポトーシス誘発作用を有するインドール誘導体
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
WO2006002887A1 (en) * 2004-06-29 2006-01-12 Baxter International Inc. Aqueous drink solution of indibulin (d-24851) and an organic acid
BRPI0517652A (pt) * 2004-11-08 2008-10-14 Baxter Healthcare Sa composições farmacêuticas nanoparticuladas de inibidores de tubulina, métodos para as suas preparações e respectivos usos
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
CN103102303B (zh) 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP5385605B2 (ja) * 2005-03-11 2014-01-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
JP2009511494A (ja) * 2005-10-06 2009-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ結合カセットトランスポーターのモジュレーター
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
MX2009001327A (es) * 2006-08-07 2009-06-05 Ironwood Pharmaceuticals Inc Compuestos de indol.
EP2091532A1 (en) * 2006-11-28 2009-08-26 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
EP1964835A1 (en) * 2007-02-28 2008-09-03 Centre National de la Recherche Scientifique Derivatives of psammaplin A, a method for their synthesis and their use for the prevention or treatment of cancer
CN101085779A (zh) * 2007-07-11 2007-12-12 中国人民武装警察部队医学院 取代吲哚－3－基草酰表鬼臼毒素衍生物及其盐及其用途
GB0715103D0 (en) * 2007-08-03 2007-09-12 Lectus Therapeutics Ltd Calcium ion channel modulators and uses thereof
GB0909441D0 (en) * 2009-06-02 2009-07-15 Univ Sheffield Novel indole derivatives
US9585810B2 (en) 2010-10-14 2017-03-07 Fresenius Medical Care Holdings, Inc. Systems and methods for delivery of peritoneal dialysis (PD) solutions with integrated inter-chamber diffuser
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
HRP20190867T1 (hr) 2011-05-12 2019-07-12 Proteostasis Therapeutics, Inc. Regulatori proteostaze
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
IN2014CN02290A (enExample) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
CN102942516B (zh) * 2012-11-05 2015-02-25 宁波大学 一种生物碱类化合物及其制备方法和应用
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
IL225540A (en) * 2013-04-02 2015-09-24 Igal Nir A method, system, and software for automatically generating a speech database for speech recognition
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
CN105198788A (zh) * 2015-09-30 2015-12-30 蒋军荣 一种吲哚氧代乙酰(n-二芳甲基)哌嗪衍生物及其制备方法和应用
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
GB1089071A (en) * 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
FR2182915A1 (en) * 1972-03-30 1973-12-14 Nelson Res & Dev Substd indoles, benzimidazoles - as anti-immune agents , antitumour agents, serotonin inhibitors, hypnotics
WO1994008581A1 (fr) * 1992-10-20 1994-04-28 Toray Industries, Inc. Inhibiteur d'infiltration d'eosinophiles
US5405864A (en) * 1993-10-15 1995-04-11 Syntex (U.S.A.) Inc. Chemotherapeutic maleimides
EP2341045A1 (en) * 1994-04-01 2011-07-06 Eli Lilly and Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor
ES2124064T3 (es) * 1995-06-07 1999-01-16 Lilly Co Eli Compuestos y composiciones con cadenas laterales nitrogenadas no basicas.
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6225329B1 (en) 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
EP1080068A1 (en) 1998-03-12 2001-03-07 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE59910142D1 (de) 1998-04-28 2004-09-09 Elbion Ag Neue hydroxyindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung
JP2000239252A (ja) 1999-02-16 2000-09-05 Mitsubishi Chemicals Corp インドール誘導体
AU4834200A (en) 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
US7205299B2 (en) 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect
DE102004031538A1 (de) 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
US20060280787A1 (en) 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof

Also Published As

Publication number Publication date
KR20010042368A (ko) 2001-05-25
DK1071420T3 (da) 2006-01-16
HUP0101530A2 (hu) 2001-11-28
DE59912562D1 (en) 2005-10-20
EP1071420A1 (de) 2001-01-31
NO327721B1 (no) 2009-09-14
BR9909902A (pt) 2000-12-26
AU768510B2 (en) 2003-12-18
ES2249884T3 (es) 2006-04-01
BG64838B1 (bg) 2006-06-30
BG104849A (en) 2001-05-31
JP2011148809A (ja) 2011-08-04
NO20004916L (no) 2000-12-01
NO20004916D0 (no) 2000-09-29
US7579365B2 (en) 2009-08-25
RU2262339C2 (ru) 2005-10-20
NZ507084A (en) 2003-10-31
CA2326833C (en) 2009-06-23
HRP20000643A2 (en) 2001-04-30
PL192779B1 (pl) 2006-12-29
EE200000581A (et) 2002-02-15
US20030195360A1 (en) 2003-10-16
JP5253696B2 (ja) 2013-07-31
WO1999051224A1 (de) 1999-10-14
RS49866B (sr) 2008-08-07
DE19814838A1 (de) 1999-10-14
IL138737A0 (en) 2001-10-31
IS5635A (is) 2000-09-22
IL138737A (en) 2007-02-11
ID26504A (id) 2001-01-11
TWI230608B (en) 2005-04-11
YU59300A (sh) 2002-11-15
PL343525A1 (en) 2001-08-27
UA70942C2 (uk) 2004-11-15
SK14302000A3 (sk) 2001-11-06
GEP20032967B (en) 2003-05-27
JP2002510622A (ja) 2002-04-09
ZA200006150B (en) 2001-01-11
HUP0101530A3 (en) 2002-12-28
KR100583545B1 (ko) 2006-05-26
US6232327B1 (en) 2001-05-15
ATE304352T1 (de) 2005-09-15
AU2934999A (en) 1999-10-25
US20030023093A1 (en) 2003-01-30
SK286393B6 (sk) 2008-09-05
AR018175A1 (es) 2001-10-31
US20080027110A1 (en) 2008-01-31
IS2307B (is) 2007-10-15
EP1071420B1 (de) 2005-09-14
TR200002853T2 (tr) 2001-02-21
DE19814838C2 (de) 2001-01-18
CA2326833A1 (en) 1999-10-14
HK1036408A1 (en) 2002-01-04
CN1299280A (zh) 2001-06-13
EE04354B1 (et) 2004-10-15

Similar Documents

Publication Publication Date Title
CN1148183C (zh) 具有抗肿瘤作用的吲哚基-3-乙醛酸衍生物
CN1227542A (zh) 具有抗哮喘、抗过敏和免疫抑制/免疫调节作用的n－取代的吲哚－3－乙醛酰胺类化合物
CN1253449C (zh) 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
CN1077571C (zh) 用于抑制细胞增殖的取代的双吲哚基马来酰亚胺
CN1287487A (zh) 氨基苯氧基乙酸衍生物和含有它们的药用组合物
CN1283637C (zh) 具有抗肿瘤活性的取代n－苄基吲哚－3－基乙醛酸衍生物
CN1182417A (zh) 吲哚衍生物
CN1610683A (zh) 作为磷酸酶抑制剂的嘧啶并三嗪
CN1437596A (zh) 苯基哌嗪基衍生物
CN1675193A (zh) 1－甲基－2－(4－脒基苯基氨甲基)－苯并咪唑－5－基－羧酸－(n－2－吡啶基－n－2－羟基羰基乙基－酰胺的新颖前药，其制法及其作为药物制剂的用途
CN1058404A (zh) 苯并咪唑的新型衍生物、其制备及其药物用途
CN1434819A (zh) 4－苯基－1－哌嗪基、－哌啶基和－四氢吡啶基衍生物
CN1258276A (zh) 细胞增生抑制剂氰基胍
CN1187333C (zh) 某些取代的己内酰胺、含有它们的药物组合物和它们在治疗肿瘤中的用途
CN1309642A (zh) 具有止喘、抗变态反应、抗炎、免疫调节和神经保护作用的新的1,2,5－三取代1,2－二氢吲唑－3－酮类化合物、其制备方法以及作为药物的应用
CN1258277A (zh) 细胞增生抑制剂氰基胍
CN1155595C (zh) 作为用于治疗癌症的抗增殖剂的取代的吡咯类化合物
HK1036408B (en) Indolyl-3-glyoxylic acid derivatives with antitumoral activity
CN1703411A (zh) 作为ccr5抑制剂的哌啶衍生物
CN1181057C (zh) 新型5-嘧啶甲酰胺衍生物和含有所述衍生物的药物组合物
CN1191486A (zh) 未取代和取代的n－(吡咯－1－基)吡啶胺作为抗惊厥药的用途
HK1083497B (en) 2,4-substituted indoles and their use as 5-ht6 modulators
HK1083497A1 (en) 2,4-Substituted indoles and their use as 5-ht6 modulators
CN1094409A (zh) 3′-氧-炔丙基-三氟胸苷的硫酯衍生物、它的制法及作为抗癌剂的用途
MXPA00009646A (en) Indolyl-3-glyoxylic acid derivatives with antitumoral activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040505

Termination date: 20150322

EXPY Termination of patent right or utility model